Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT801 in Moderate to Severe Refractory Autoimmune Diseases
NCT07614191Phase 1Recruiting
- Sponsor
- Vivacta
- Start
- May 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GT801 in autoimmune disease, sponsored by Vivacta. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 3 months. Started May 2026; status: recruiting.
02
Drugs
GT801
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT07614191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07614191.